WallStSmart

Apimeds Pharmaceuticals US, Inc. (APUS)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

APUS leads profitability with a 0.0% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

APUS

Avoid

19

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 5.0Quality: 7.3
Piotroski: 2/9

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APUS2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

APUS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$25.91M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : APUS

The strongest argument for APUS centers on Debt/Equity, Price/Book.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : APUS

The primary concerns for APUS are Revenue Growth, EPS Growth, Market Cap.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

APUS profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS is growing revenue faster at 5.0% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (50/100 vs 19/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Apimeds Pharmaceuticals US, Inc.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company in the United States. The company is headquartered in Hopewell, New Jersey.

Visit Website →

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?